Objective To determine the efficacy and safety of treatment with rituximab plus methotrexate
(MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to …

Background Etanercept, which blocks the action of tumor necrosis factor, reduces disease
activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease …

Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …

Objective To examine the efficacy and safety of the humanized anti–interleukin‐6 receptor
antibody tocilizumab combined with conventional disease‐modifying antirheumatic drugs (…

Objective To compare the clinical and radiographic outcomes in patients with rheumatoid
arthritis (RA) who received monotherapy with either etanercept or methotrexate (MTX) for 2 …

… MC Genovese10 … Mean high-sensitivity C-reactive protein was within the normal range
from week 12 with tocilizumab, whereas levels remained elevated with methotrexate. The …

We constructed miniaturized autoantigen arrays to perform large-scale multiplex characterization
of autoantibody responses directed against structurally diverse autoantigens, using …

The immune system has evolved specialized cellular and molecular mechanisms for
targeting and regulating immune responses at epithelial surfaces. Here we show that small …

Objective: The phase III GO-FORWARD study examined the efficacy and safety of golimumab
in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. Methods: …

Background In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced
disease activity in patients with rheumatoid arthritis who had not previously received …